Elizabeth A. Grimm - Publications

Affiliations: 
The University of Texas Graduate School of Biomedical Sciences at Houston 
Area:
Cell Biology, Molecular Biology, Immunology

55 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R, Ekmekcioglu S, Grimm EA, Roszik J. High-Throughput Architecture for Discovering Combination Cancer Therapeutics. Jco Clinical Cancer Informatics. 1-12. PMID 30652536 DOI: 10.1200/CCI.17.00054  0.56
2018 Kim SH, Roszik J, Cho SN, Ogata D, Milton DR, Peng W, Menter D, Ekmekcioglu S, Grimm EA. The COX2 effector microsomal PGE2 synthase-1 is a regulator of immunosuppression in cutaneous melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30538110 DOI: 10.1158/1078-0432.CCR-18-1163  0.56
2018 Dal Yontem F, Kim SH, Ding Z, Grimm E, Ekmekcioglu S, Akcakaya H. Mitochondrial dynamic alterations regulate melanoma cell progression. Journal of Cellular Biochemistry. PMID 30256441 DOI: 10.1002/jcb.27518  0.56
2018 Kim SH, Roszik J, Grimm EA, Ekmekcioglu S. Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy. Frontiers in Oncology. 8: 67. PMID 29616189 DOI: 10.3389/fonc.2018.00067  0.56
2017 Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, Jazaeri AA, Roszik J. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Frontiers in Immunology. 8: 689. PMID 28670312 DOI: 10.3389/fimmu.2017.00689  0.56
2017 Qin Y, Conley AP, Grimm EA, Roszik J. A tool for discovering drug sensitivity and gene expression associations in cancer cells. Plos One. 12: e0176763. PMID 28453553 DOI: 10.1371/journal.pone.0176763  0.32
2017 Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, Putluri N, Ekmekcioglu S, Grimm EA, Dong C, Overwijk WW. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor. Neoplasia (New York, N.Y.). 19: 237-249. PMID 28254151 DOI: 10.1016/j.neo.2016.07.009  0.56
2017 Ekmekcioglu S, Grimm EA, Roszik J. Targeting iNOS to increase efficacy of immunotherapies. Human Vaccines & Immunotherapeutics. 0. PMID 28121247 DOI: 10.1080/21645515.2016.1276682  0.56
2016 Bailey P, Chang DK, Forget MA, Lucas FA, Alvarez HA, Haymaker C, Chattopadhyay C, Kim SH, Ekmekcioglu S, Grimm EA, Biankin AV, Hwu P, Maitra A, Roszik J. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports. 6: 35848. PMID 27762323 DOI: 10.1038/srep35848  0.56
2016 Qin Y, Roszik J, Chattopadhyay C, Hashimoto Y, Liu C, Cooper ZA, Wargo JA, Hwu P, Ekmekcioglu S, Grimm EA. Hypoxia-driven mechanism of vemurafenib resistance in melanoma. Molecular Cancer Therapeutics. PMID 27458138 DOI: 10.1158/1535-7163.MCT-15-0963  0.56
2016 Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaeli B, Grimm EA, Wargo JA, Woodman SE, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. Cancer. PMID 26991400 DOI: 10.1002/cncr.29727  0.32
2016 Kim SH, Hashimoto Y, Cho SN, Roszik J, Milton DR, Dal F, Kim SF, Menter DG, Yang P, Ekmekcioglu S, Grimm EA. Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression. Pigment Cell & Melanoma Research. PMID 26801201 DOI: 10.1111/pcmr.12455  0.56
2016 Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, Woodman SE, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26783288 DOI: 10.1158/1078-0432.CCR-15-2226  0.56
2015 Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, et al. Dual Roles of RNF2 in Melanoma Progression. Cancer Discovery. PMID 26450788 DOI: 10.1158/2159-8290.CD-15-0493  0.56
2015 Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. The Journal of Investigative Dermatology. PMID 26178706 DOI: 10.1038/jid.2015.259  0.56
2015 Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. The Journal of Investigative Dermatology. 135: 2775-84. PMID 26039541 DOI: 10.1038/jid.2015.204  0.56
2015 Qin Y, Milton DR, Oba J, Ding Z, Lizée G, Ekmekcioglu S, Grimm EA. Inflammatory IL-1β-driven JNK activation in stage III melanoma. Pigment Cell & Melanoma Research. 28: 236-9. PMID 25546243 DOI: 10.1111/pcmr.12348  0.56
2014 Maturu P, Overwijk WW, Hicks J, Ekmekcioglu S, Grimm EA, Huff V. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors. Translational Oncology. 7: 484-92. PMID 24969538 DOI: 10.1016/j.tranon.2014.05.008  0.56
2014 Lopez-Rivera E, Jayaraman P, Parikh F, Davies MA, Ekmekcioglu S, Izadmehr S, Milton DR, Chipuk JE, Grimm EA, Estrada Y, Aguirre-Ghiso J, Sikora AG. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Research. 74: 1067-78. PMID 24398473 DOI: 10.1158/0008-5472.CAN-13-0588  0.56
2013 Grimm EA, Sikora AG, Ekmekcioglu S. Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5557-63. PMID 23868870 DOI: 10.1158/1078-0432.CCR-12-1554  0.56
2013 Qin Y, Deng W, Ekmekcioglu S, Grimm EA. Identification of unique sensitizing targets for anti-inflammatory CDDO-Me in metastatic melanoma by a large-scale synthetic lethal RNAi screening. Pigment Cell & Melanoma Research. 26: 97-112. PMID 23020131 DOI: 10.1111/pcmr.12031  0.56
2012 Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5329-40. PMID 22850568 DOI: 10.1158/1078-0432.CCR-12-1632  0.56
2012 Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of activated c-Met with NRAS-mutated human melanomas. International Journal of Cancer. 131: E56-65. PMID 22020736 DOI: 10.1002/ijc.26487  0.56
2012 Tanese K, Grimm EA, Ekmekcioglu S. The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. International Journal of Cancer. 131: 891-901. PMID 21953496 DOI: 10.1002/ijc.26451  0.56
2011 Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizée G, Poindexter N, Grimm EA. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Molecular Cancer Research : McR. 9: 1537-50. PMID 21954434 DOI: 10.1158/1541-7786.MCR-11-0279  0.56
2011 Ekmekcioglu S, Chattopadhyay C, Akar U, Gabisi A, Newman RA, Grimm EA. Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells. Nutrition and Cancer. 63: 940-9. PMID 21745040 DOI: 10.1080/01635581.2011.586488  0.56
2011 Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 229-35. PMID 20975100 DOI: 10.1158/1078-0432.CCR-10-2276  0.56
2011 Deng WG, Kwon J, Ekmekcioglu S, Poindexter NJ, Grimm EA. IL-24 gene transfer sensitizes melanoma cells to erlotinib through modulation of the Apaf-1 and Akt signaling pathways. Melanoma Research. 21: 44-56. PMID 20216471 DOI: 10.1097/CMR.0b013e3283382155  0.56
2010 Sikora AG, Gelbard A, Davies MA, Sano D, Ekmekcioglu S, Kwon J, Hailemichael Y, Jayaraman P, Myers JN, Grimm EA, Overwijk WW. Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1834-44. PMID 20215556 DOI: 10.1158/1078-0432.CCR-09-3123  0.56
2008 Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, Chada S. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Molecular Cancer Therapeutics. 7: 3842-51. PMID 19056673 DOI: 10.1158/1535-7163.MCT-08-0516  0.56
2008 Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Research. 18: 241-5. PMID 18626307 DOI: 10.1097/CMR.0b013e3283046146  0.56
2008 Ekmekcioglu S, Mumm JB, Udtha M, Chada S, Grimm EA. Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine. 43: 34-44. PMID 18511292 DOI: 10.1016/j.cyto.2008.04.010  0.56
2008 Grimm EA, Ellerhorst J, Tang CH, Ekmekcioglu S. Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis. Nitric Oxide : Biology and Chemistry / Official Journal of the Nitric Oxide Society. 19: 133-7. PMID 18472017 DOI: 10.1016/j.niox.2008.04.009  0.92
2007 Zheng M, Priebe W, Walch ET, Roth KG, Han M, Tang CH, Lee S, Poindexter NJ, Fokt I, Grimm EA. WP760, a melanoma selective drug. Cancer Chemotherapy and Pharmacology. 60: 625-33. PMID 17195067 DOI: 10.1007/s00280-006-0404-5  0.92
2007 Zheng M, Bocangel D, Doneske B, Mhashilkar A, Ramesh R, Hunt KK, Ekmekcioglu S, Sutton RB, Poindexter N, Grimm EA, Chada S. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10 Cancer Immunology, Immunotherapy. 56: 205-215. PMID 16710719 DOI: 10.1007/s00262-006-0175-1  0.56
2006 Mumm JB, Ekmekcioglu S, Poindexter NJ, Chada S, Grimm EA. Soluble human MDA-7/IL-24: characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 26: 877-86. PMID 17238830 DOI: 10.1089/jir.2006.26.877  0.56
2006 Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS predicts poor survival for stage III melanoma patients. International Journal of Cancer. 119: 861-6. PMID 16557582 DOI: 10.1002/ijc.21767  0.56
2006 Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene. 25: 3956-62. PMID 16474847 DOI: 10.1038/sj.onc.1209419  0.56
2005 Poindexter NJ, Walch ET, Chada S, Grimm EA. Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells. Journal of Leukocyte Biology. 78: 745-52. PMID 16000394 DOI: 10.1189/jlb.0205116  0.48
2005 Chada S, Bocangel D, Ramesh R, Grimm EA, Mumm JB, Mhashilkar AM, Zheng M. mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 724-33. PMID 15851011 DOI: 10.1016/j.ymthe.2004.12.021  0.48
2005 Ekmekcioglu S, Tang CH, Grimm EA. NO news is not necessarily good news in cancer. Current Cancer Drug Targets. 5: 103-15. PMID 15810875  0.92
2005 Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 160-72. PMID 15585417 DOI: 10.1016/j.ymthe.2004.09.021  0.56
2004 Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, Zheng M, Grimm EA, Ekmekcioglu S. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 1085-95. PMID 15564140 DOI: 10.1016/j.ymthe.2004.08.020  0.56
2004 Zheng M, Ekmekcioglu S, Walch ET, Tang CH, Grimm EA. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Research. 14: 165-71. PMID 15179184  0.92
2004 Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA, Hunt KK, Fuson KL, Poìndexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM. MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. International Immunopharmacology. 4: 649-67. PMID 15120650 DOI: 10.1016/j.intimp.2004.01.017  0.56
2004 Tang CH, Grimm EA. Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. The Journal of Biological Chemistry. 279: 288-98. PMID 14576150 DOI: 10.1074/jbc.M310821200  0.92
2003 Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, Prieto VG, Stewart AL, Mhashilkar AM, Chada S, Grimm EA. Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells. Molecular Cancer Therapeutics. 2: 9-17. PMID 12533668  0.56
2002 Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Molecular Cancer Therapeutics. 1: 1009-17. PMID 12481423  0.56
2002 Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Mumm JB, Zumstein L, Watson GJ, Snary D, Roth JA, Grimm EA, et al. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Molecular Medicine (Cambridge, Mass.). 8: 451-61. PMID 12435856  0.56
2002 Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S, Grimm EA. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. Journal of Immunology (Baltimore, Md. : 1950). 168: 6041-6. PMID 12055212  0.56
2002 Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm EA. Loss of MDA-7 expression with progression of melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1069-74. PMID 11844832 DOI: 10.1200/JCO.20.4.1069  0.56
2001 Ekmekcioglu S, Ellerhorst J, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, Grimm EA. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. International Journal of Cancer. 94: 54-9. PMID 11668478 DOI: 10.1002/ijc.1437  0.56
2000 Caudell EG, Caudell JJ, Tang CH, Yu TK, Frederick MJ, Grimm EA. Characterization of human copine III as a phosphoprotein with associated kinase activity. Biochemistry. 39: 13034-43. PMID 11041869  0.92
2000 Yu TK, Caudell EG, Smid C, Grimm EA. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. Journal of Immunology (Baltimore, Md. : 1950). 164: 6244-51. PMID 10843677  0.52
1996 Frederick MJ, Yu TK, Krohn EG, Johnston DA, Grimm EA. Protein tyrosine kinase inhibition blocks granule exocytosis and cytolytic function of lymphokine-activated killer cells. Immunopharmacology. 35: 83-102. PMID 8956972  0.52
Show low-probability matches.